Tectonic Therapeutic Inc
TECX21.156USD
+0.426+2.06%
Horário de mercado （ET）Cotações atrasadas em 15 min
395.01MValor de mercado
PerdaP/L TTM
Mais detalhes de Tectonic Therapeutic Inc Empresa
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).
Informações da empresa
Código da empresaTECX
Nome da EmpresaTectonic Therapeutic Inc
Data de listagemJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Número de funcionários51
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 21
Endereço490 Arsenal Way
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Telefone13396663320
Sitehttps://tectonictx.com/
Código da empresaTECX
Data de listagemJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 22 de jul
Atualizado em: ter, 22 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
Investidores
Investidores
Proporção
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
Tipos de investidores
Investidores
Proporção
Individual Investor
27.37%
Hedge Fund
24.98%
Investment Advisor
22.57%
Corporation
10.93%
Investment Advisor/Hedge Fund
7.56%
Venture Capital
2.74%
Research Firm
2.25%
Pension Fund
0.12%
Family Office
0.05%
Other
1.43%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
178
18.44M
98.77%
+1.52M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Prosight Capital
398.88K
2.14%
+398.88K
--
Mar 31, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.8%
iShares Micro-Cap ETF
Proporção0.05%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
iShares Biotechnology ETF
Proporção0.02%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Data
Tipo
Proporção
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
